RVL Pharmaceuticals plc

RVLPQ

IE00BF2HDL56

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 20:51:15 19/04/2024 BST			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		0.00%	0.00%

04-12	North American Morning Briefing : Big Banks Kick -2-	DJ
03-21	North American Morning Briefing : Investors -2-	DJ

RVL Pharmaceuticals plc to Discuss First Quarter 2022 Financial Results and Provide Commercial Update

May 05, 2022 at 06:01 pm

BRIDGEWATER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its first quarter 2022 financial results and provide a commercial update on Thursday, May 12, 2022, before U.S. financial markets open.

Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Mike DePetris, Interim Chief Financial Officer, will host a conference call as follows:

Date		Thursday, May 12, 2022
Time		8:30 a.m. ET
Toll free (U.S.)		866-342-8591
International		203-518-9713
Conference ID		RVLPQ122
Webcast (live and replay)		www.rvlpharma.com under the “Investors & News” section

About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ^® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.

Investor and Media Relations for RVL Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Source: RVL Pharmaceuticals plc

2022 GlobeNewswire, Inc., source Press Releases

Latest news about RVL Pharmaceuticals plc

North American Morning Briefing : Big Banks Kick -2-	04-12	DJ
North American Morning Briefing : Investors -2-	03-21	DJ
North American Morning Briefing : TSMC Results -2-	01-18	DJ
North American Morning Briefing : Focus Fixed on Latest Inflation Print	01-11	DJ
North American Morning Briefing : S&P 500 Futures -2-	01-04	DJ
North American Morning Briefing : S&P 500 Futures Just Shy of Record High	12-28	DJ
North American Morning Briefing : Stock Futures -2-	12-21	DJ
North American Morning Briefing : Dow Set For New -2-	12-14	DJ
North American Morning Briefing : Stock Futures Struggle to Extend Rally Ahead of More Jobs Data	12-07	DJ
RVL Pharmaceuticals plc(NasdaqGS:RVLP) dropped from S&P TMI Index	25/10/23	CI
RVL Pharmaceuticals plc(NasdaqGS:RVLP) dropped from NASDAQ Composite Index	20/10/23	CI
Health Care Down as Risk Aversion Hurts Biotech -- Health Care Roundup	12/10/23	DJ
Sector Update: Health Care Stocks Decline in Late Afternoon	12/10/23	MT
Top Midday Decliners	12/10/23	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	12/10/23	MT
RVL Pharmaceuticals Subsidiaries File for Prepackaged Chapter 11 Change of Control to Lenders	12/10/23	MT
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	29/09/23	MT
Top Premarket Gainers	29/09/23	MT
RVL Pharmaceuticals plc Announces Resignation of Joaquin Benes and Juan Vergez from the Board of Directors	22/09/23	CI
HC Wainwright Adjusts RVL Pharmaceuticals Price Target to $3 From $4, Maintains Buy Rating	21/08/23	MT
Sector Update: Health Care Stocks Decreasing Late Afternoon	16/08/23	MT
Sector Update: Health Care	16/08/23	MT
Top Midday Decliners	16/08/23	MT
Transcript : RVL Pharmaceuticals plc, Q2 2023 Earnings Call, Aug 14, 2023	14/08/23
Earnings Flash (RVLP) RVL PHARMACEUTICALS Posts Q2 Revenue $8.3M, vs. Street Est of $10.3M	14/08/23	MT

Chart RVL Pharmaceuticals plc

Duration

Period

More charts

Company Profile

RVL Pharmaceuticals plc is a specialty pharmaceutical company. The Company is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. It is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. The Company is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. Its healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and practitioners qualified to diagnose and treat acquired blepharoptosis in adults.

Sector

Pharmaceuticals

Calendar

08/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
RVL PHARMACEUTICALS PLC	0.00%	111
CSL LIMITED	-3.45%	87.17B
SAMSUNG BIOLOGICS CO.,LTD.	+1.97%	40.1B
UCB	+56.78%	25.12B
BIOMARIN PHARMACEUTICAL INC.	-14.82%	15.59B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-8.82%	12B
INCYTE CORPORATION	-16.29%	11.8B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.58%	11.8B
SWEDISH ORPHAN BIOVITRUM AB	+6.14%	8.81B
INNOVENT BIOLOGICS, INC.	-10.41%	8.24B

Biopharmaceuticals